The estimated Net Worth of Hans Lennart Rudolf Wigzell is at least $5.42 Million dollars as of 8 March 2024. Hans Wigzell owns over 15,000 units of Sarepta Therapeutics Inc stock worth over $4,858,278 and over the last 12 years he sold SRPT stock worth over $0. In addition, he makes $562,165 as Independent Director at Sarepta Therapeutics Inc.
Sign up
Hans Wigzell SRPT stock SEC Form 4 insiders trading
Hans has made over 9 trades of the Sarepta Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of SRPT stock worth $208,500 on 8 March 2024.
The largest trade he's ever made was exercising 15,000 units of Sarepta Therapeutics Inc stock on 8 March 2024 worth over $208,500. On average, Hans trades about 3,623 units every 100 days since 2012. As of 8 March 2024 he still owns at least 37,840 units of Sarepta Therapeutics Inc stock.
You can see the complete history of Hans Wigzell stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Hans Wigzell biography
Dr. Hans Lennart Rudolf Wigzell M.D., Ph.D. serves as Independent Director of the Company. In the past five years, Dr. Wigzell has served as a member of our Board since June 2010. He also serves as a member of our nominating and corporate governance committee and a member of and chair of our research and development committee. In the past five years, Dr. Wigzell served as a director of Probi AB, Swedish Orphan Biovitrum AB and Valneva SE (a successor to Intercell AG), a biotechnology company, and currently serves as Chairman of Rhenman & Partners Asset Management AB, an investment management firm, and a director of RaySearch Laboratories AB, a medical technology company. Since 2006, Dr. Wigzell has served as a director of Karolinska Development AB, a company listed on the NASDAQ OMX Stockholm market that selects, develops and seeks ways to commercialize promising new Nordic lifescience innovations. He has also served as the Chairman of Karolinska Development AB since 2017. From 1995 to 2003, he was the President of the Karolinska Institute, a medical university and was General Director of the National Bacteriological Laboratory in Stockholm from 1987 to 1993. Dr. Wigzell is Chairman of the board of the Stockholm School of Entrepreneurship. He is an elected member of several national academies, including the Swedish Royal Engineering Academy, Sweden; the Royal Academy of Science, Sweden; the Danish Academy of Arts and Letters; the American Academy of Arts and Sciences; the Finnish Science Society; and the European Molecular Biology Organization. In addition to serving as President of the Karolinska Institute, his academic career includes being Chairman of the Nobel Prize Committee, and the Karolinska Institute and Distinguished External Advisory Professor of Ehime University, Japan. Additionally, Dr. Wigzell was appointed Chairman of the Nobel Assembly in 2000. Dr. Wigzell holds an M.D. and Ph.D.
What is the salary of Hans Wigzell?
As the Independent Director of Sarepta Therapeutics Inc, the total compensation of Hans Wigzell at Sarepta Therapeutics Inc is $562,165. There are 12 executives at Sarepta Therapeutics Inc getting paid more, with Gilmore O'Neill having the highest compensation of $5,168,110.
How old is Hans Wigzell?
Hans Wigzell is 82, he's been the Independent Director of Sarepta Therapeutics Inc since 2010. There are no older and 17 younger executives at Sarepta Therapeutics Inc.
What's Hans Wigzell's mailing address?
Hans's mailing address filed with the SEC is 215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, 02142.
Insiders trading at Sarepta Therapeutics Inc
Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry, and M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.
What does Sarepta Therapeutics Inc do?
sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
What does Sarepta Therapeutics Inc's logo look like?
Complete history of Hans Wigzell stock trades at Sarepta Therapeutics Inc
Sarepta Therapeutics Inc executives and stock owners
Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Gilmore O'Neill,
Executive Vice President, R&D and Chief Medical Officer -
William Ciambrone,
Executive Vice President - Technical Operations -
David Howton,
Executive Vice President, General Counsel, Secretary -
Alexander Cumbo,
Executive Vice President and Chief Commercial Officer -
Douglas Ingram,
President, Chief Executive Officer, Director -
Douglas S. Ingram,
Pres, CEO & Director -
Dr. Gilmore O'Neill M.D.,
Exec. Officer -
Dr. Louise Rodino-Klapac Ph.D.,
Chief Scientific Officer and Head of R&D -
Ian Michael Estepan,
Exec. VP & CFO -
William F. Ciambrone,
Exec. VP of Technical Operations -
M. Kathleen Behrens,
Independent Chairwoman of the Board -
Richard Barry,
Independent Director -
Hans Wigzell,
Independent Director -
Claude Nicaise,
Independent Director -
Mary Gray,
Independent Director -
John Martin,
Independent Director -
Joseph Bratica,
Interim Principal Financial and Accounting Officer -
Dr. Diane L. Berry,
Sr. VP of Global Health Policy and Gov. & Patient Affairs -
Alison Nasisi,
Chief People Officer & VP -
Ryan E. Brown,
Sr. VP, Gen. Counsel & Corp. Sec. -
Mary Jenkins,
Sr. Mang. of Investor Relations -
Michael W Bonney,
Director -
Ben Gil Price,
Director -
Catherine Stehman Breen,
SVP, Chief Medical Officer -
Jayant Aphale,
SVP Technical Operations -
Jean Paul Kress,
Director -
William Alden Goolsbee,
Director -
Shamim Ruff,
SVP, Chief Regulatory Affairs -
Sandesh Mahatme,
EVP, CFO & CBO -
Guriqbal S. Basi,
SVP, Chief Scientific Officer -
Michael A Jacobsen,
VP of Finance and PAO -
Anthony Martignetti,
-
Nishan Garabedian Christopher,
President and CEO -
Anthony R Chase,
Director -
John Hodgman,
Director -
Arthur M Krieg,
SVP, Chief Scientific Officer -
Edward M. Md Kaye,
SVP & Chief Medical Officer -
Ian Michael Estepan,
Chief Financial Officer -
Ryan Edward Brown,
EVP, General Counsel -
Louise Rodino Klapac,
Head of R&D, CSO -
Bilal Arif,
Chief Tech Ops Officer -
Stephen Mayo,
-
Kathryn Jean Boor,
-
Dallan Murray,
Chief Customer Officer